These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8559143)

  • 1. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5.
    Evans MJ; Rollins SA; Wolff DW; Rother RP; Norin AJ; Therrien DM; Grijalva GA; Mueller JP; Nye SH; Squinto SP
    Mol Immunol; 1995 Nov; 32(16):1183-95. PubMed ID: 8559143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.
    Thomas TC; Rollins SA; Rother RP; Giannoni MA; Hartman SL; Elliott EA; Nye SH; Matis LA; Squinto SP; Evans MJ
    Mol Immunol; 1996 Dec; 33(17-18):1389-401. PubMed ID: 9171898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation.
    Kroshus TJ; Rollins SA; Dalmasso AP; Elliott EA; Matis LA; Squinto SP; Bolman RM
    Transplantation; 1995 Dec; 60(11):1194-202. PubMed ID: 8525509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs.
    Rollins SA; Matis LA; Springhorn JP; Setter E; Wolff DW
    Transplantation; 1995 Dec; 60(11):1284-92. PubMed ID: 8525523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of complement molecular complex C5b-9 (C5b-9) in response to poly-traumatic hemorrhagic shock and evaluation of C5 cleavage inhibitors in non-human primates.
    Paredes RM; Reyna S; Vernon P; Tadaki DK; Dallelucca JJ; Sheppard F
    Int Immunopharmacol; 2018 Jan; 54():221-225. PubMed ID: 29156357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.
    Fung M; Lu M; Fure H; Sun W; Sun C; Shi NY; Dou Y; Su J; Swanson X; Mollnes TE
    Clin Exp Immunol; 2003 Aug; 133(2):160-9. PubMed ID: 12869020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies.
    Marzari R; Sblattero D; Macor P; Fischetti F; Gennaro R; Marks JD; Bradbury A; Tedesco F
    Eur J Immunol; 2002 Oct; 32(10):2773-82. PubMed ID: 12355429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The release of C5a in complement-activated serum does not require C6.
    Biesecker G; Wagner JL; Hugli TE
    J Immunol; 1989 Aug; 143(4):1228-32. PubMed ID: 2545783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
    Hammer CH; Hänsch G; Gresham HD; Shin ML
    J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of complement activation in the isolated heart. Role of the terminal complement components.
    Homeister JW; Satoh P; Lucchesi BR
    Circ Res; 1992 Aug; 71(2):303-19. PubMed ID: 1628389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.
    Nilsson PH; Thomas AM; Bergseth G; Gustavsen A; Volokhina EB; van den Heuvel LP; Barratt-Due A; Mollnes TE
    Mol Immunol; 2017 Sep; 89():111-114. PubMed ID: 28610663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative inefficiency of terminal complement activation.
    Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
    J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart.
    Homeister JW; Satoh PS; Kilgore KS; Lucchesi BR
    J Immunol; 1993 Feb; 150(3):1055-64. PubMed ID: 8423331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.
    Fitch JC; Rollins S; Matis L; Alford B; Aranki S; Collard CD; Dewar M; Elefteriades J; Hines R; Kopf G; Kraker P; Li L; O'Hara R; Rinder C; Rinder H; Shaw R; Smith B; Stahl G; Shernan SK
    Circulation; 1999 Dec 21-28; 100(25):2499-506. PubMed ID: 10604887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway.
    Krisinger MJ; Goebeler V; Lu Z; Meixner SC; Myles T; Pryzdial EL; Conway EM
    Blood; 2012 Aug; 120(8):1717-25. PubMed ID: 22802338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments.
    Boel E; Verlaan S; Poppelier MJ; Westerdaal NA; Van Strijp JA; Logtenberg T
    J Immunol Methods; 2000 May; 239(1-2):153-66. PubMed ID: 10821956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species.
    Zelek WM; Morgan BP
    Front Immunol; 2020; 11():612402. PubMed ID: 33424866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine.
    Wang H; Jiang J; Liu W; Kubelik D; Chen G; Gies D; Garcia B; Zhong R; Rother RP
    Transplantation; 2005 May; 79(9):1121-7. PubMed ID: 15880054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation.
    De Vries B; Matthijsen RA; Wolfs TG; Van Bijnen AA; Heeringa P; Buurman WA
    Transplantation; 2003 Feb; 75(3):375-82. PubMed ID: 12589162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.